source
- Bausch + Lomb and Celldex rocked by respective phase 2 flopsBausch + Lomb and Celldex have independently reported phase 2 flops. While Celldex ended work in the indication in response to the setback, Bausch + Lomb noted numerical improvements and explorator…Fierce Biotech · 8h ago↗ source
- Novartis CEO says AI could cut drug development time and boost success ratesAt an investor event in London, Novartis chief executive Vas Narasimhan, who also sits on the board of AI company Anthropic, explained how the Swiss drugmaker is turning to artificial intelligence…
- FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapy